IsoRay (ISR) Stock: Will Gains Continue?

IsoRay, Inc. (NYSEMKT: ISR)

I’ve been following IsoRay for quite some time now. Ever since I heard about Cesium-131, I’ve been interested in the company. While the stock hasn’t performed well over the past year, I believe that current data coming out with regard to the Cesium-131 treatment may change that in a big way. In fact, as a result of recent data, ISR is seeing a decline in short interest. Today, we’ll take a look at the short interest surrounding ISR and why Cesium-131 will likely lead to growth.

IsoRay Sees A Large Decline In Short Interest

Short interest is incredibly important for an investor to watch. After all, there are two ways to go about trading a stock, short or long. Those that trade short believe that the value of the stock is likely to decline. So, by watching short interest, it’s possible to get a clear depiction of investor sentiment surrounding the stock. With that said, ISR has seen a decent decline in short interest. In fact, as of December 31st, short interest on ISR totaled 4,838,632 shares. That proved to be a decline of 8.2% from December 15th, when the total was 5,270,933 shares. This is great news showing that investors are starting to have more faith in the stock.

Recent Data With Regard To Cesium-131

IsoRay recently released the results of a study that looked into the cost effectiveness of Cesium-131. According to their study, Cesium-131 is more cost effective than the current standard of care which is surgical resection and stereotactic radiosurgery. In fact, the company found through the study that Cesium-131 costs less than half what surgical resection and stereotactic radiosurgery runs. According to ISR, the cost of Cesium-131 and hospital costs come in at a total of $19,271. However, for surgical resection and stereotactic radiosurgery and the hospital costs that come along with it, the price climbs to $44,219. This is incredibly positive news that could lead to a shift in how brain metastases are treated.

Other Reasons Cesium-131 Is The Better Option

When it comes to IsoRay’s Cesium-131, there are several other reasons that the treatment is far better than the current standard of care making ISR a strong investment prospect. Here’s why Cesium-131 is a strong option:

  • Length Of Treatment – When it comes to the alternative, patients must undergo a long-term treatment plan. However, in the case of Cesium-131, the treatment plan is simple. In fact, the treatment is only administered once.
  • Side Effects – It’s also important to note that side effects are common in the treatment of cancer. When it comes to Cesium-131 there are side effects, but those side effects are nowhere near as bad as those that are associated with other treatment options.
  • Effects On Family, Friends, and Caregivers – Finally, it’s important to remember that patients have family and friends as well as people that take care of them. With some radioactive isotopes, family and friends have to worry about the radioactivity of the patient. However, because the radioactive isotope associated with Cesium-131 has a half life of just a few days, family and friends do not have to be concerned about their health when visiting the patient.

The Bottom Line

The bottom line here is that Cesium-131 has proved to be the better option when treating several different forms of cancer. This is great news for ISR and its investors. Considering the fact that a recent study showed that the treatment created by ISR comes at a lower cost with more benefits, consumers will be more interested in taking advantage of the treatment, ultimately leading to gains. So, if you’re considering investing in ISR, you may just be on the right path.

What Do You Think?

Where do you think ISR is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Add Comment